The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is VRd or RAd induction more efficacious for patients with NDMM undergoing risk-adapted auto-SCT?

Jul 27, 2020

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Stefan Knop, University Hospital of Würzburg, Würzburg, DE. We asked: Is bortezomib, lenalidomide, and dexamethasone (VRd) or lenalidomide, adriamycin, and dexamethasone (RAd) induction more efficacious for patients with newly diagnosed multiple myeloma (NDMM) undergoing risk-adapted autologous stem cell transplantation (auto-SCT)?

Is VRd or RAd induction more efficacious for patients with NDMM undergoing risk-adapted auto-SCT?

In this video, Stefan Knop describes the phase III study that tested this and explains the 2x2 factorial design based on the very good partial response (VGPR) rates reached by patients. Discussed here are median progression-free survival (PFS) and overall survival results; 3-year PFS will be discussed in a publication later this year.